Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$14 Mln
P/E Ratio
--
P/B Ratio
0
Industry P/E
--
Debt to Equity
-1.13
ROE
0 %
ROCE
-375.67 %
Div. Yield
0 %
Book Value
--
EPS
-2.15
CFO
$-482.26 Mln
EBITDA
$-583.57 Mln
Net Profit
$-658.34 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Accelerate Diagnostics (AXDX)
| -55.53 | -23.77 | -56.97 | -42.63 | -61.70 | -65.58 | -45.62 |
|
BSE Sensex*
| 2.55 | 3.65 | 4.54 | 7.46 | 12.04 | 19.65 | 11.41 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Accelerate Diagnostics (AXDX)
| -69.09 | -44.48 | -86.40 | -31.13 | -55.15 | 46.96 | -55.91 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 12.69 | 10,202.62 | 12.01 | 12.69 | |
| 72.33 | 10,025.34 | 96.83 | 2.52 | |
| 163.14 | 8,863.93 | -- | -25.23 | |
| 296.91 | 11,513.99 | 277.87 | 3.65 |
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States and internationally. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the... identification and antibiotic susceptibility testing (AST) of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides Accelerate PhenoTest BC Kit, a test kit for the system, which is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. In addition, the company offers Accelerate Arc system, an instrument and associated one-time-use test kit that automates the clean-up and concentration of microbial cells from positive blood culture samples. Further, it develops Accelerate WAVE system, which performs AST directly from positive blood culture bottles and bacterial isolate colonies to report minimum inhibitory concentrations. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona. Address: 3950 South Country Club Road, Tucson, AZ, United States, 85714 Read more
CEO, President & Director
Mr. Jack Phillips
CEO, President & Director
Mr. Jack Phillips
Headquarters
Tucson, AZ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Accelerate Diagnostics Inc (AXDX) stood at $ 29 Mln as on 31-Dec-24
The share price of Accelerate Diagnostics Inc (AXDX) is $0.53 (NASDAQ) as of 29-Apr-2025 16:00 EDT. Accelerate Diagnostics Inc (AXDX) has given a return of -61.7% in the last 3 years.
Accelerate Diagnostics Inc (AXDX) has a market capitalisation of $ 14 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Accelerate Diagnostics Inc (AXDX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Accelerate Diagnostics Inc (AXDX) and enter the required number of quantities and click on buy to purchase the shares of Accelerate Diagnostics Inc (AXDX).
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States and internationally. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing (AST) of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides Accelerate PhenoTest BC Kit, a test kit for the system, which is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. In addition, the company offers Accelerate Arc system, an instrument and associated one-time-use test kit that automates the clean-up and concentration of microbial cells from positive blood culture samples. Further, it develops Accelerate WAVE system, which performs AST directly from positive blood culture bottles and bacterial isolate colonies to report minimum inhibitory concentrations. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona. Address: 3950 South Country Club Road, Tucson, AZ, United States, 85714
The CEO & director of Mr. Jack Phillips. is Accelerate Diagnostics Inc (AXDX), and CFO & Sr. VP is Mr. Jack Phillips.
There is no promoter pledging in Accelerate Diagnostics Inc (AXDX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,078
|
|
|
1,054
|
|
|
964
|
|
|
853
|
| Accelerate Diagnostics Inc. (AXDX) | Ratios |
|---|---|
|
Return on equity(%)
|
131.82
|
|
Operating margin(%)
|
-316.24
|
|
Net Margin(%)
|
-427.81
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Accelerate Diagnostics Inc (AXDX) was $0 Mln.
$0.00
(
